Home/Pipeline/QL335

QL335

Colorectal Cancer

Phase 1Active

Key Facts

Indication

Colorectal Cancer

Phase

Phase 1

Status

Active

Company

QLSF Biotherapeutics

About QLSF Biotherapeutics

QLSF Biotherapeutics is a private, clinical-stage biotech founded in 2020 and headquartered in South San Francisco, California. The company has built a robust pipeline of novel bispecific antibodies and cytokine fusion proteins targeting multiple immune-oncology mechanisms, with several programs already in Phase 1/2 clinical trials. Its strategy is driven by tumor biology, categorizing approaches for 'Myeloid Rich,' 'Immunologically Cold,' and 'Inflamed' tumor microenvironments. QLSF benefits from strong financial and clinical development support from a strategic partner, Qilu Pharmaceutical, which is advancing key assets in clinical studies.

View full company profile

Therapeutic Areas

Oncology

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
M9140	Merck KGaA	Phase 1/2	Active
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
Cannabics® RCC-33	CNBX Pharmaceuticals	Preclinical	Preparation of Pre-IND Meeting Package
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active
KRAS AK™PCR Mutation Screen Kit	Akcell Biotech	Commercial	Active